The USFDA has recently approved a paclitaxel-coated balloon catheter to treat coronary in-stent restenosis (ISR) in patients with coronary artery diseases (CAD). The device was designed to transfer the drug to the vessel wall to prevent the reoccurrence of in-stent restenosis. Clinical evidence The efficiency of paclitaxel-coated balloon catheter was evaluated in a clinical trial involving 480 patients. The device demonstrated superiority over uncoated balloon angioplasty in attaining the primary endpoint of target lesion failure at 12 months (17.9% vs.
28.7%). In addition, the device produced no probable or definite cases of clotting within the stent and reduced heart attack risk at the target vessel by 49%. Furthermore, it was associated with low adverse event rates at 12 months. Contraindication Use in the cerebrovascular/supra-aortic arteries Unprotected native left main CAD…
